Phase I multiple ascending dose trial of BAL 30072 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2013
At a glance
- Drugs BAL 30072 (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; Pharmacokinetics
- 25 Jun 2013 Maximum tolerated dose has been reached (dose-limiting factor was reversible elevated liver enzyme levels), according to Basilea Pharmaceutica media release.
- 07 Dec 2012 New trial record